Vitamin D status and peripheral arterial disease: evidence so far by Chua, GT et al.
© 2011 Chua et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2011:7 671–675
Vascular Health and Risk Management
Vitamin D status and peripheral arterial disease: 
evidence so far
GT Chua
YC Chan
SW Cheng
Division of Vascular Surgery, 
Department of Surgery,  
University of Hong Kong Medical 
Centre, Queen Mary Hospital, 
Pokfulam, Hong Kong
Correspondence: Yiu Che Chan 
Division of Vascular and Endovascular  
Surgery, Department of Surgery,  
University of Hong Kong Medical Centre,  
South Wing, 14th Floor Block K,  
Queen Mary Hospital, Pokfulam,  
Hong Kong 
Tel +852 2255 4962 
Fax +852 2255 4961 
Email ycchan88@ hkucc.hku.hk
Background: Vitamin D deficiency has recently been implicated as a contributory factor in 
the development of peripheral arterial disease (PAD).
Methods: A review of the published literature on PAD and vitamin D was undertaken using 
Medline, PubMed, and Embase, and cross-referenced. All relevant published papers on the 
subject were reviewed.
Results: Published studies have shown that there is a significant association between vitamin D 
and PAD. Populations with lower vitamin D levels are more likely to develop PAD in a graded 
manner. Higher amputation rates are also observed among patients with PAD and lower 
vitamin D levels. In addition, vitamin D deficiency is significantly associated with increased 
risk of cardiovascular adverse events. This was also observed in the mouse model where low 
vitamin D led to the development of atherosclerosis.
Conclusion: This study shows that vitamin D deficiency could be an independent risk factor 
for the development of PAD and that this risk factor is easily correctable. Further studies should 
look into the effects of vitamin D supplementation in patients with PAD.
Keywords: peripheral arterial disease, claudication, gangrene, vitamin D deficiency,   amputation, 
cardiovascular risk factors
Introduction
It is now more than 75 years since the discovery of calciferol, known commonly as 
vitamin D, and of its ability to cure rickets in animals and children.1–3 Recent epide-
miologic and clinical studies have indicated that vitamin D may have far more roles 
than just in the prevention of rickets. Diseases such as osteoporosis, muscle weakness, 
several types of cancer, diabetes, hypertension, and cardiovascular disease may all 
result from subtle and chronic vitamin D deficiency.4
Vitamin D is a generic name for a group of fat-soluble steroids of which the two major 
forms are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol).5 Vitamin D, 
or calciferol, without a subscript, refers to either D2, D3, or both. In 1919, a British 
doctor, Edward Mellanby, noticed that dogs fed cod liver oil did not develop rickets 
and concluded that cod liver oil could prevent the disease.6 In 1921, Elmer McCollum 
tested modified cod liver oil in which the vitamin A had been destroyed, which also 
cured sick dogs, so McCollum concluded that the factor in cod liver oil which cured 
rickets was distinct from vitamin A.7–9 It was called “vitamin D” because it was the 
fourth vitamin to be named, following an alphabetical code. The molecular geometry 
of vitamin D2 was determined in 193210 and that of vitamin D3 in 1936 as a result of 
ultraviolet irradiation of 7-dehydrocholesterol.11
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Measurements of serum vitamin D 
levels
The concentration of 25-hydroxyvitamin D (25-OHD) is 
commonly used for measurement of serum vitamin D levels, 
despite the active form being 1,25-OHD. This is because 
parathyroid hormone will increase renal conversion when 
there is an insufficiency, causing the active form to be normal 
or elevated. Therefore, vitamin D status is better reflected by 
25-OHD. However, measurement of 25-OHD levels may not 
be accurate in patients with severe renal diseases (creatinine 
clearance less than 15 mL/min or undergoing dialysis), as 
renal conversion of 25-OHD level is reduced. Hence, para-
thyroid hormone levels should also be taken into account 
when identifying vitamin D deficiency.12
There is no consensus regarding the cut-off level for 
vitamin D deficiency. It has been suggested previously that 
vitamin D deficiency in adults should be defined as a serum 
25-OHD level below 50 nmol/L (20 ng/mL).12,13 However, 
further research suggests that optimal serum 25-OHD status 
should be maintained above 80 nmol/L (32 ng/mL), because 
the risk for various medical conditions, including reduced 
bone density, periodontal disease, colon cancer, hypertension, 
and impaired lung function, is lowest above this level. The 
risk of undiagnosed diabetes and impaired glucose tolerance 
was also found to be lowest when the serum 25-OHD level 
was above 83 nmol/L; while that of myocardial infarction was 
lowest when serum 25-OHD was above 107 nmol/L.13
Technically, there are still some uncertainties about the 
optimal method for measuring vitamin D levels. Multiple 
methodologies for 25-OHD measurement (radioimmunoas-
say, high-performance liquid chromatography, and liquid 
chromatography tandem mass spectroscopy) are available 
and subject to variability, which causes difficulties in defining 
the cut-off value for vitamin D insufficiency or deficiency. 
Therefore, aiming at a higher 25-OHD level seems to be 
clinically safe and reasonable, as it improves vitamin D status 
with minimal risks.14 Most laboratories have increased the 
lower limit of the reference range to 75 nmol/L (30 ng/mL). 
In addition, 25-OHD level varies with seasons, exposure to 
sunlight, and dietary intake.15 Therefore, unless issues such 
as choice of assay, timing of measurement, and reference 
range are clearly addressed, the optimal method of measuring 
vitamin D level remains uncertain.
Literature search method and 
results
A literature review using standard databases including 
PubMed, Medline, and Embase was performed in March 
2011, searching for studies on peripheral arterial disease 
and vitamin D and its analogs performed since 2000. The 
search was conducted using the keywords “peripheral 
arterial disease” (PAD) and “vitamin D.” Inclusion criteria 
were: systematic reviews and meta-analysis, journal reviews, 
cohort, case-control studies and population studies, and 
English-language articles where the full text was available. 
Commentaries and letters to the editor were excluded.
Twenty-three articles were initially identified and 13 of 
these excluded. Five articles had no full text available, five 
articles were irrelevant to the topic, two articles were letters 
to the editor, and one was commentary. The remaining ten 
articles were included for review. These included journal 
reviews, longitudinal, and cross-sectional studies, written 
in English with full text available. Publications on the rela-
tionships between vitamin D and cardiovascular risk factors, 
cardiovascular diseases, and peripheral arterial disease were 
carefully reviewed. Other relevant articles were also cross-
referenced.
Vitamin D deficiency and 
cardiovascular risk factors
Vitamin D deficiency has been shown in various studies to be 
associated with an increase in the prevalence of various car-
diovascular risk factors.16–19 Vitamin D deficiency is inversely 
correlated with body mass index, hypertension, diabetes mel-
litus, and hyperlipidemia (total cholesterol and triglyceride).16 
When subjects were categorized into normal (.30 ng/mL 
or 75 nmol/L), low (16–30 ng/mL or 40–75 nmol/L) or very 
low (#15 ng/mL or 37.5 nmol/L) vitamin D level groups, 
it was also found that there were highly significant graded 
inverse associations with hypertension, hyperlipidemia, dia-
betes mellitus, and PAD. In addition, there was an increase 
in hazard ratios for these cardiovascular risk factors between 
individuals with very low and normal vitamin D levels, which 
remained statistically significant after adjustment.17
In a randomized placebo-controlled double-blind trial, 
Witham et al found that one single dose of high-dose vitamin D2 
improves endothelial function, as assessed by flow-  mediated 
dilatation of the brachial artery in response to 5 minutes of 
forearm occlusion.18 Values were significantly higher in the 
intervention group at 8 weeks’ follow-up, despite the blood 
pressures of subjects not being significantly affected during 
the short-term follow-up period of 16 weeks.18,19
Vitamin D inadequacy has also been shown to be inversely 
correlated with the proliferation of vascular smooth muscle 
cells,20,21 inflammatory effects upon arterial endothelial 
cells, and with increased carotid intima-media thickness.22,23 
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Vitamin D deficiency is linked to adverse morphological 
changes in large arteries, even in children.24 Low vitamin 
D has been shown to affect survival rate independently of 
vascular calcification and stiffness.25 Calcification can be 
induced by 1,25-OHD in cultured arterial smooth muscle 
cells.26 Arterial calcification is common in patients with 
diabetes and end-stage renal failure with peripheral arterial 
disease, and paricalcitol, a vitamin D receptor agonist, has 
been shown to improve survival for renal failure patients 
in comparison to traditional calcitriol therapy.27 Reik et al 
found that 1,25-OHD affects macrophages by lowering acety-
lated and oxidized low-density lipoprotein uptake in type 
2 diabetic patients, thus reducing foam-cell formation and 
subsequently atherosclerosis.28 In addition, 1,25-OHD can 
induce cell-cycle arrest and apoptosis, an important process 
in the development of atherosclerosis and in some normal and 
malignant cell types.29 More recently, vitamin D deficiency 
has been associated with peripheral vascular disease,30 and 
may be an important contributory factor in the development 
of peripheral arterial disease in different ethnicities.
Gaddipati et al reviewed the possible mechanisms and role 
of vitamin D in vascular health.30 Vitamin D decreases blood 
pressure through the renin-angiotensin system.31 Vitamin D 
deficiency is inversely related to vascular smooth muscle 
proliferation and increase in carotid intima-media thickness. 
However, excessive vitamin D may do more harm than good, 
as excessive dietary consumption is potentially angiotoxic.32 
Such toxicity can lead to vascular calcification and arte-
rial stiffness. Norman and Powell showed that 1,25-OHD 
(which is the active form of vitamin D) interacts with vitamin 
D receptors and directly or indirectly regulates the expression 
of a number of proteins relevant to the arterial wall, such as 
vascular endothelial growth factor, matrix metalloproteinase 
type 9, myosin, and elastin, and type I collagen. Cultured 
arterial smooth muscles can also undergo calcification when 
treated with 1,25-OHD, through a mechanism relying on 
suppression of parathyroid hormone–related peptide, which 
is an endogenous inhibitor of calcification, and parathyroid 
hormone–receptor signaling. Directly or indirectly, vitamin D 
exposure may downregulate the paracrine mechanism that 
normally protects the vasculature from calcification.33
Vitamin D deficiency and 
cardiovascular diseases
Cardiovascular diseases and adverse events are significantly 
higher in subjects with very low vitamin D levels. These 
conditions include coronary artery disease, heart failure, 
atrial fibrillation, PAD, stroke, myocardial infarction; the 
rate of death is also significantly higher in subjects with 
very low vitamin D levels.17,34,35 In another study, Wang et al 
also analyzed the relationship between vitamin D and risk 
of cardiovascular disease, and found that participants with 
25-OHD levels , 15 ng/mL (37.5 nmol/L) had a higher 
incidence of cardiovascular events compared with those with 
25-OHD . 15 ng/mL, with a hazard ratio (HR) of 1.62. Simi-
lar observations were made in participants with hypertension 
(HR = 2.13, 95% confidence interval [CI] 1.30–3.48), but 
there were no significant differences between participants 
without hypertension (HR = 1.04, 95% CI 0.55–1.96). 
A graded inverse relationship between cardiovascular risk 
and 25-OHD level was also observed in this study.36 These 
results suggest that vitamin D deficiency may potentially 
become a future risk factor for cardiovascular diseases.
However, these results may not be conclusive. A recent 
systematic review and meta-analysis was unable to dem-
onstrate a statistically significant reduction in mortality 
and cardiovascular risks, including stroke and myocardial 
infarction, but the quality of the available evidence was low 
to moderate at best.37 However, another systematic review 
by Grandi et al showed significant results.38 Therefore, clini-
cal association between vitamin D and cardiovascular risks 
and events should be further investigated and supported by 
high-quality evidence.
Vitamin D deficiency and peripheral 
arterial disease
Recent studies have suggested that vitamin D may have a 
direct relationship with PAD.16,39–40 Reis et al performed 
a cross-sectional study based on the National Health and 
Nutrition Examination Survey 2001–2004, investigating 
racial differences in vitamin D levels and the incidence of 
PAD between black and white populations.39 The authors 
concluded that Afro-Caribbean populations were at higher 
risk of vitamin D deficiency, possibly due to greater cutaneous 
melanin content, lower dietary intake, and racial differences 
in vitamin D metabolism. They also showed that vitamin 
D concentrations were significantly lower in blacks that in 
whites (P , 0.001) and PAD was significantly more prevalent 
among black adults than white (8.5% and 5.3% respectively, 
P , 0.05), with the odds ratio being 2.11. After adjustment 
for demographic factors and cardiovascular risk factors 
(diabetes, hypertension, hypercholesterolemia, C-reactive 
protein, estimated glomerulofiltration rate, and history of 
cardiovascular disease), the odds ratio remained significant 
at 1.67. In contrast, adjustment for serum 25-OHD concen-
tration yielded insignificant results.
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Serum vitamin D level has been shown to have an inverse 
relationship with the prevalence of PAD in a graded manner. 
Melamed et al studied the association between 25-OHD levels 
and prevalence of PAD, and found that for each 10 ng/mL 
decrease in 25-OHD, the prevalence ratio of PAD was 1.35 (95% 
CI 1.15–1.59) after multivariable adjustment. Furthermore, 
vitamin D deficiency increases the amputation rate in patients 
with PAD.40 Gaddipati et al showed that individuals with vitamin 
D deficiency (,20 ng/mL) had a significantly higher amputa-
tion rate compared with those who were not defined as vitamin 
D deficient (6.7% and 4.2%, P = 0.029).16
Experimental evidence
Emerging laboratory evidence supports the idea of a direct 
relationship between vitamin D and PAD. Oral supplementa-
tion of vitamin D3 has been shown to suppress atheroscle-
rosis in a mouse model. Takeda et al tested apolipoprotein 
E-knock-out mice with calcitriol and demonstrated that 
higher doses of calcitriol reduced the formation of athero-
sclerotic lesions by 39.1%, which was significantly more 
than those in the control group. It was shown in the athero-
sclerotic lesions that more regulatory T-cells (Tregs) and less 
mature dendritic cells are present compared with the control 
group.41 Studies have shown that Tregs suppress the inflam-
matory responses of effector T-cells, which are suggested to 
be potentially proatherogenic, while dendritic cells stimulate 
the differentiation of naive T-cells to effector T-cells.21,42,43 In 
addition, Takeda et al has also demonstrated that suppression 
of Tregs has resulted in an increase in atherosclerotic lesions. 
This showed that oral vitamin D3 reduces atherosclerosis by 
the suppression of inflammatory cells in mice, which warrants 
confirmation of such benefits in humans.41
All the above findings imply that vitamin D deficiency 
is an important direct contributor to PAD in a dose-related 
manner and proper supplementation could possibly reverse 
the disease. Vitamin D deficiency could also affect subse-
quent adverse events.
Limitations of the current review
There are several limitations to this review. Firstly, most of 
the studies included were population-based, cross-sectional, 
or longitudinal studies. Only associations, not causal rela-
tionships, could be established between vitamin D and PAD. 
Although most studies concluded that vitamin D deficiency 
was a potential risk factor of PAD, it was also sensible to 
think that vitamin D deficiency could be a complication of 
PAD as a result of impaired mobility and subsequent lack of 
sunlight exposure. Secondly, there was a lack of information 
about certain aspects in these studies, including the geo-
graphical location of residence, seasonal variations during 
which blood samples were obtained, and measurement of 
parathyroid hormone, which were significant confounding 
variables. Thirdly, these studies were targeted to Western 
populations. The associations between vitamin D and PAD 
in Asians or other ethnic populations, such as those of Arabic 
descent, remain unclear. Currently, there is still no level-
one evidence or any randomized-controlled trials studying 
whether vitamin D supplementation is useful in reducing the 
rate or the risk of developing PAD, so a systematic review 
or meta-analysis of randomized-controlled trials is not yet 
possible.
Conclusion
Emerging studies are showing that there is an association 
between low vitamin D levels and PAD, with animal mod-
els suggesting possible mechanisms. Future studies should 
focus on various ethnic populations, and investigate whether 
vitamin D should be recommended for prevention of PAD, 
and if so, at what dosage. Only randomized controlled trials 
will be able to provide the answers.
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